Cyclerion Therapeutics, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge, MA
SEC filing record 1 source field available
Fiscal year end
31 December
Cyclerion Therapeutics, Inc. has filed 344 SEC EDGAR filings since 09 Oct 2018

SEC filing history

Showing 1-8 of 8 matching filings.

Per page
25
Current page
1
SC 13D/A File 005-90979

SC 13D/A

Filing date
05 Dec 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-90979

SC 13D/A

Filing date
23 May 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-90979

SC 13D/A

Filing date
12 May 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-90979

SC 13D/A

Filing date
03 Apr 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-90979

SC 13D/A

Filing date
21 Nov 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D File 005-90979

SC 13D filing

Filing date
21 Oct 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-90979

SC 13DA

Filing date
07 Jun 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D File 005-90979

SC 13D

Filing date
14 May 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .